Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

PHASE2/PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

January 29, 2021

Conditions

COVID-19

Interventions

DRUG

Olokizumab 64 mg

solution for subcutaneous administration 160 mg/mL

DRUG

Placebo

Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package